Descurainia Sophia in hemodialysis patients

Evaluating the effects of Descurainia Sophia on serum inflammatory markers and thirst alleviation in hemodialysis patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170725035305N3

Enrollment

Registered

2019-08-09

Start date

2018-12-22

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemodialysis patients. Chronic kidney disease, stage 5

Interventions

Intervention 1: The first intervention group (n = 30) initially received an extract of Descuria.Sophia containing 2 grams of D,Sophia powder and half a gram of brown sugar with 100 cc of water for 4 w

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: age between 18 - 70 years old on hemodialysis for more than 3 months KT/V > 1.2 insensitive to D. Sophia or any herbal remedy no history of active infection in the past month using AVF for Hemodialysis

Exclusion criteria

Exclusion criteria: sensitivity to D. Sophia or any herbal remedy history of active infection in the past month unwilling to participate for any reason using permcath or AVG for hemodialysis hospital admission for any reason in past month and during the study period.

Design outcomes

Primary

Measure	Time frame
MDA (Malondialdehyde). Timepoint: At the start of the study, before wash out, after wash out and at the end of the study. Method of measurement: serum level and biochemistry analysis.;Potassium serum level. Timepoint: At the start of the study, before wash out, after wash out and at the end of the study. Method of measurement: blood sample.;Lipid profile. Timepoint: At the start of the study, before wash out, after wash out and at the end of the study. Method of measurement: blood sample.;Total antioxidation capacity. Timepoint: At the start of the study, before wash out, after wash out and at the end of the study. Method of measurement: blood sample.;Hemocystein serum level. Timepoint: At the start of the study, before wash out, after wash out and at the end of the study. Method of measurement: blood sampling.	—

Measure

Time frame

MDA (Malondialdehyde). Timepoint: At the start of the study, before wash out, after wash out and at the end of the study. Method of measurement: serum level and biochemistry analysis.;Potassium serum level. Timepoint: At the start of the study, before wash out, after wash out and at the end of the study. Method of measurement: blood sample.;Lipid profile. Timepoint: At the start of the study, before wash out, after wash out and at the end of the study. Method of measurement: blood sample.;Total antioxidation capacity. Timepoint: At the start of the study, before wash out, after wash out and at the end of the study. Method of measurement: blood sample.;Hemocystein serum level. Timepoint: At the start of the study, before wash out, after wash out and at the end of the study. Method of measurement: blood sampling.

—

Secondary

Measure	Time frame
Thirst intensity. Timepoint: At the start of the study, before wash out, after wash out and at the end of the study. Method of measurement: using Visual Analogue Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmirhesam Alirezaei

Shahid Beheshti University of Medical Sciences

amirhesam124@gmail.com+212 2083112

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026